← Insights
9 November 2026 · 7 min read · Vedant, Founder

The data gap: why risk tools built elsewhere misjudge Indian patients

A clinical risk tool is a summary of the patients it was built on. When the patients in front of a doctor differ from those patients, the tool’s numbers can be wrong in ways that are hard to see from the outside.

Most of the risk tools used in Indian clinics were derived from European or North American cohorts. This article looks at two of them — one for heart disease, one for breast cancer — and at what it takes to build tools that are calibrated for Indian patients.

Heart disease arrives earlier

Indians develop cardiovascular disease about six years earlier than Europeans: the mean age of a first heart attack is around 53, against 58.8 in Europe. Roughly 62% of cardiovascular deaths in India are premature, compared with 28–35% in Western countries.

SCORE2, the European Society of Cardiology’s 2021 risk model, was derived from 677,684 people in European cohorts, with no South Asian representation. The HEART Score, widely used for chest pain in emergency departments, was developed in the Netherlands. Neither was built to account for several patterns that are common in Indian patients:

  • Higher risk at lower body weight. South Asian BMI cut-offs are 23 and 27.5 kg/m², against 25 and 30 for Europeans.
  • A distinct cholesterol pattern, with high triglycerides and low HDL, better captured by the TG/HDL ratio.
  • Smokeless tobacco — gutkha, paan, khaini — which behaves differently from cigarette smoking.
  • Diabetes, which raises cardiovascular risk three to four times more than European models assume.

A tool that misses these factors tends to underestimate risk, and an underestimate can mean a patient who would benefit from treatment is told they are low-risk.

Breast cancer presents younger

In India, breast cancer presents at a mean age of about 47, against 62–64 in Western countries. Triple-negative disease makes up around 25% of cases, against 12–15% in the West. HER2-positive rates are higher, disease is more often advanced at diagnosis, and access to adjuvant therapy follows different patterns.

INFLUENCE 3.0, a well-regarded model for predicting locoregional recurrence, was derived from more than 36,000 patients in the Netherlands Cancer Registry. It has never been prospectively validated on Indian cohorts, so there is no evidence that its estimates are calibrated for Indian patients.

What closing the gap takes

Recalibrating an existing model to Indian averages can help, but it cannot add variables the model never had. Closing the gap properly means three things. First, Indian data: prospective cohorts such as CARRS and PURE India, hospital and state registries, and published Indian studies. Second, models that include India-specific variables from the start and handle competing risks correctly. Third, published documentation — model cards, datasheets and risk summaries — so that clinicians and regulators can check what a tool was built on and where it fails.

Where AlgoMD is

AlgoMD is working on both problems. CardioPredict-India (CPI) and INDIRA are at the data-acquisition stage. Neither is available for clinical use, and neither has been reviewed by CDSCO or any other regulator. We will publish their documentation on our Research page as it is written, and progress in Lab Notes.

Sources

SCORE2 working group and ESC Cardiovascular Risk Collaboration, European Heart Journal, 2021. Six et al., HEART Score, Netherlands Heart Journal, 2008. Van Maaren et al., INFLUENCE nomogram, Netherlands Cancer Registry. Indian epidemiological figures as compiled in AlgoMD’s CPI and INDIRA research files; full citations will be added to each model card.

This article is general information, not medical advice. Talk to your doctor about your own risk.